Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629941 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
A Phase 4 study of Blepharitis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT00629941: Completed Phase 4 study of Blepharitis, sponsored by Merck Sharp & Dohme.
NCT00629941 is a Phase 4 study of Blepharitis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 25 participants, below the 56-participant average among 6 other Blepharitis trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00629941, a Phase 4 study of Blepharitis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs \& symptoms of blepharitis and tear cytokine and eyelid bacterial load levels
Conditions Studied
Interventions
- DRUG AzaSite®
Study Locations (2)
Maine
- Central Maine Eye Care - Lewiston
Massachusetts
- Ophthalmic Research Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-03 |
| Phase | Phase 4 |
What the finished NCT00629941 record still lists
NCT00629941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 56-participant average among 6 other Blepharitis trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Blepharitis appearing as the primary indexed condition, and to 1 intervention - of which AzaSite® is the first listed.
NCT00629941 reports a single indexed study location in Maine, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00629941 about?
NCT00629941 is a clinical study titled "Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis". The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs \& symptoms of blepharitis and tear cytokine and eyelid bacterial load levels
What is the current status of trial NCT00629941?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2008-03.
What conditions does trial NCT00629941 study?
This clinical trial studies the following conditions: Blepharitis.
What interventions are being tested in trial NCT00629941?
The interventions under investigation include: AzaSite® (DRUG).
Who is sponsoring clinical trial NCT00629941?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00629941 being conducted?
This trial has 2 study locations across Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blepharitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
COMPLETED · Phase 4
-
Evaluation of SUMMIT BRUSH in Treatment of Blepharitis
RECRUITING · NA
-
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
ACTIVE NOT RECRUITING · Phase 2
-
Corneal Epithelial Stem Cells and Dry Eye Disease
COMPLETED · NA
-
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
COMPLETED · Phase 3
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia